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In previous  studies,  we  demonstrated  that  12-month  treatment  with  0.75  g/day  eldecalcitol  increased
bone  mineral  density  in osteoporotic  patients  regardless  of serum  25-hydroxyvitamin  D (25(OH)D)  level,
and in a  3-year  randomized  double-blind  clinical  trial,  eldecalcitol  signiﬁcantly  reduced  the  incidences  of
vertebral  and  wrist  fractures  compared  to alfacalcidol.  However,  it remains  unclear  whether  the  fracture
risk reduction  by  eldecalcitol  is  affected  by  serum  25(OH)D.  In the  fracture  prevention  trial,  patients  with
low 25(OH)D  level  at baseline  were supplemented  with  400  IU/day  native  vitamin  D3.  In  the  current
study,  patients  from  that  trial were  divided  according  to the  tertiles  of serum  25(OH)D  level at  6  months
after  treatment  initiation.  The  increases  in  lumbar  and  hip  BMD  by  eldecalcitol  were  signiﬁcantly  higher
in all  tertiles  than  those  by alfacalcidol.  The  incidences  of vertebral  and  osteoporotic  fractures  tended  to  be
lower  in  each  tertile  of the  eldecalcitol-treated  group  than  in  the corresponding  tertile  of the  alfacalcidol-
treated  group,  with  the  exception  of vertebral  fractures  in  the  low  tertile.  We  also  investigated  whether
eldecalcitol  treatment  affected  levels  of  serum  25(OH)D,  serum  1,25(OH)2D,  and  parathyroid  hormone  in
patients  without  vitamin  D  supplementation.  With  eldecalcitol  treatment,  serum  1,25(OH)2D  concentra-
tion  was  reduced  by  approximately  50%,  whereas  serum  levels  of parathyroid  hormone  and  25(OH)D  were
not affected.  The  major  ﬁndings  of the  present  study  were  that  eldecalcitol  did  not  affect  serum  25(OH)D
levels,  and  that  it reduced  the  incidence  of  osteoporotic  fractures  and  increased  BMD  in comparison  with
alfacalcidol  regardless  of  serum  25(OH)D  level  within  the  range  of  serum  25(OH)D  concentrations  at  or
higher than  20 ng/mL.  Whether  eldecalcitol  is  similarly  effective  at vitamin  D  deﬁcient  serum  25(OH)D
levels  remains  to be  clariﬁed.
This  article  is  part  of a  Special  Issue  entitled  ‘Vitamin  D Workshop’.. Introduction
Active vitamin D3 (calcitriol; 1,25-dihydroxyvitamin D3;
,25(OH)2D3) is a key regulator of metabolism in the bone, intes-
ine, keratinocytes, pancreatic cells, and immune cells [1]. A meta-
nalysis of the effect of vitamin D compounds indicated that admin-
stration of vitamin D compounds reduces the risk of vertebral
ractures by 37% in patients with postmenopausal osteoporosis [2].
 This is an open-access article distributed under the terms of the Creative
ommons Attribution License, which permits unrestricted use, distribution and
eproduction in any medium, provided the original author and source are credited.
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Eldecalcitol is a new calcitriol analog that bears a hydrox-
ypropyloxy substituent at the 2 position of calcitriol. In a fracture
prevention trial comparing alfacalcidol and eldecalcitol, eldecalci-
tol signiﬁcantly increased lumbar and total hip BMD  and reduced
the incidences of vertebral and wrist fractures [3]. The effect of elde-
calcitol on vertebral fractures was  not affected by 25(OH)D value
at baseline. However, because patients with low levels of 25(OH)D
(below 20 ng/mL) at baseline were supplemented with 400 IU of
native vitamin D3, it was  not known whether 25(OH)D concen-
tration during the study period affected the treatment effect of
eldecalcitol. And although eldecalcitol strongly induces CYP24A1
from the data of the animal study [4], it remains unknown whether
eldecalcitol has a possibility to inﬂuence the concentration of serum
25(OH)D. The present study is a post hoc analysis of the frac-
ture prevention trial to investigate the relation between 25(OH)D
concentration during the study period and the efﬁcacy of eldecal-
citol. We  also investigated the inﬂuence of eldecalcitol on serum
25(OH)D concentration.
reserved.
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Table  1
Baseline characteristics of enrolled patients divided according to each tertile of serum 25(OH)D level at 6 months. The tertile boundaries are following; low (<29.5 ng/mL),
middle  (≥29.5 to <37.3 ng/mL), and high (≥37.3 ng/mL).
Eldecalcitol Alfacalcidol
Low Middle High Low Middle High
(n  = 180) (n = 174) (n = 152) (n = 152) (n = 166) (n = 186)
Age (years) 72.1 72.1 72.4 71.8 72.2 72.1
BMI  (kg/m2) 22.3 22.4 22.1 22.4 22.5 22.2
No.  of prevalent vertebral fractures
0 (%) 68 (38) 66 (38) 56 (37) 58(38) 62 (37) 66 (35)
1  (%) 50 (28) 54 (31) 46 (30) 43 (28) 54 (33) 58 (31)
≥2  (%) 62 (34) 54 (31) 50 (33) 51 (34) 50 (30) 62 (33)
Lumbar BMD  T-score −2.66 −2.77 −2.66 −2.69 −2.81 −2.66
Total  hip BMD  T-score −2.23 −2.23 −2.33 −2.37 −2.22 −2.23
25(OH)D (ng/mL) 23.3 22.2 21.8 23.8 23.0 20.7
Intact  PTH (pg/mL) 36.5 37.0 38.8 36.5 38.3 40.3
2
e
w
c
w
(
2
w
d
s
a
s
m
o
l
b
a
a
b
a
s
w
o
a
a
a
t
h
a
o
o
i
r
d
t
r
f
“
m
d
D
H1,25(OH)2D (pg/mL) 46.9 50.6 
No.  of vitamin D suppl (%) 17 (9) 73 (42) 
. Subjects and methods
Details of the double-blind fracture prevention clinical study of
ldecalcitol have been published previously. Brieﬂy, 1054 patients
ith primary osteoporosis were divided into two  groups: an elde-
alcitol group (n = 528) and an alfacalcidol group (n = 526). They
ere given either oral eldecalcitol (0.75 g) or oral alfacalcidol
1.0 g) once a day for 3 years (36 months). Patients with serum
5(OH)D values lower than 20 ng/mL at the time of enrollment
ere given an oral native vitamin D3 supplement (400 IU) once a
ay without calcium supplementation. The primary endpoint of the
tudy was the incidence of new non-traumatic vertebral fractures,
nd the secondary endpoints were the percent change in lumbar
pine BMD  and total hip BMD, percent change of bone turnover
arkers, and incidence of non-vertebral fractures. The incidence
f new non-traumatic vertebral fractures was evaluated by using
ateral radiographs of the thoracic and lumbar spine obtained at
aseline and at 6, 12, 24, and 36 months after initiation of drug
dministration. Three expert investigators independently evalu-
ted the vertebrae from T4 to L4.
In the current study, serum 25(OH)D was originally measured
y Nichols Allegro Lite (Nichols Institute). However, because the
ssay became unavailable during the study, we  re-assessed all the
amples by HPLC – competitive protein binding assay (CPBA), in
hich 25(OH)D was ﬁrst puriﬁed by HPLC and then the amount
f 25(OH)D in the 25(OH)D fraction was measured by CPBA. As
 result, the baseline serum 25(OH)D became higher than those
ssayed by Nichols assay. Patients were stratiﬁed into tertiles
ccording to their 25(OH)D level at 6 months after treatment initia-
ion (low tertile: <29.5 ng/mL; middle tertile: ≥29.5 to <37.3 ng/mL;
igh tertile: ≥37.3 ng/mL). We  investigated the change in lumbar
nd total hip BMD, and the incidence of vertebral fractures, “all
steoporotic fractures”, and “non-vertebral osteoporotic fractures”
ccurring in each tertile at 6, 12, 24, and 36 months after treatment
nitiation.
“Osteoporotic fractures” are deﬁned by WHO  as fractures whose
isk of incidence is associated with low bone mass and whose inci-
ences rise with age after the age of 50 years. Fractures pertinent to
hese criteria are those of the spine, distal forearm (wrist), humerus,
ibs, clavicle/scapula/sternum, pelvis, tibia/ﬁbula, hip, and other
emoral fractures. “Non-vertebral osteoporotic fractures” means
osteoporotic fractures” other than fractures of the spine.
The value of 25(OH)D was evaluated at 6, 12, 24, and 36
onths after treatment initiation for all patients in each group
ivided into patients who received or did not receive vitamin
 supplementation. The values of 1,25(OH)2D (as assessed by
PLC-radioreceptor assay) and intact PTH (Eclusys PTH; Roche51.5 48.2 49.1 51.2
111 (73) 9 (6) 56 (34) 129 (69)
Diagnostics, Penzberg, Germany) were evaluated at 6, 12, 24, and
36 months after treatment initiation for all patients in each group
divided according to the tertile of 25(OH)D value at 6 months.
3. Results and discussion
There were no marked differences in baseline characteristics
regardless of serum 25(OH)D level at 6 months after treatment ini-
tiation in any of the groups except for the proportion of patients
receiving vitamin D supplementation (Table 1).
Eldecalcitol signiﬁcantly increased lumbar BMD  from baseline
by 3.3% in the low tertile, 3.1% in the middle tertile, and 4.0% in
the high tertile at 36 months, whereas alfacalcidol changed lumbar
BMD  by 0.40% in the low tertile, −0.22% in the middle tertile, and
0.17% in the high tertile at 36 months (Fig. 1A). Eldecalcitol also
signiﬁcantly increased total hip BMD  from baseline by 0.25% in the
low tertile, 0.48% in the middle tertile, and 0.50% in the high tertile
at 36 months, whereas alfacalcidol changed total hip BMD  by −2.6%
in the low tertile, −2.2% in the middle tertile, and −2.1% in the high
tertile at 36 months (Fig. 1B). The increase in lumber and hip BMD
by eldecalcitol was signiﬁcantly higher than that by alfacalcidol in
all the tertiles at 36 months.
The incidences of vertebral fractures, “osteoporotic fractures,”
and “non-vertebral osteoporotic fractures” are indicated in Fig. 2.
In each tertile, the incidence of fractures tended to be lower with
eldecalcitol treatment than with alfacalcidol treatment.
Changes in calcium regulating hormones are shown in Fig. 3.
In patients receiving vitamin D3 supplementation, serum 25(OH)D
increased in both the eldecalcitol and alfacalcidol treatment groups,
whereas in patients without vitamin D3 supplementation, serum
25(OH)D did not change in either treatment group (Fig. 3A). Serum
1,25(OH)2D decreased by approximately 50% in all tertiles of the
eldecalcitol treatment groups, whereas, 1,25(OH)2D increased by
approximately 20% in all tertiles of the alfacalcidol treatment group
(Fig. 3B). Serum PTH levels were slightly suppressed in all tertiles
of both the eldecalcitol and alfacalcidol treatment groups (Fig. 3C).
We previously demonstrated that, compared to treatment with
1.0 g/day alfacalcidol, treatment with 0.75 g/day eldecalcitol
increased BMD  and reduced the risk of vertebral and wrist frac-
tures in patients with osteoporosis. In this post hoc analysis, we
investigated whether the effect of eldecalcitol was  affected by
serum 25(OH)D concentration during treatment. We  found that
the effect of eldecalcitol on lumbar and total hip BMD  and on ver-
tebral, “osteoporotic,” and “non-vertebral osteoporotic” fractures
was similar in all tertiles of serum 25(OH)D concentration at 6
months.
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Fig. 1. Change in BMD  in eldecalcitol and alfacalcidol treated group. The BMD  values in (A) lumbar spine, and (B) total hip for both eldecalcitol- and alfacalcidol-treated groups
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Because a sufﬁcient level of serum 25(OH)D is needed to make
steoporotic drugs work, in most clinical trials of osteoporotic
rugs (bisphosphonates, SERMs [selective estrogen receptor
odulators], and so on) patients receive supplemental native
itamin D and calcium [5–7]. Ishijima et al. reported that in osteo-
orotic patients treated with alendronate, the increase in BMD  was
reater in patients with a serum 25(OH)D concentration of above
5 ng/mL at baseline than in patients whose baseline 25(OH)D con-
entration was below 25 ng/mL [8]. In contrast, in the case of active
itamin D compound, one may  expect to see a greater effect on
MD  in subjects with low serum 25(OH)D. However, in the present
tudy, among 15 subjects with serum 25(OH)D below 20 ng/mL,
here was a large variation in the change in lumbar BMD  by eldecal-
itol. Therefore, it is difﬁcult to draw any conclusions about whether
he effect of eldecalcitol on BMD  is affected by serum 25(OH)D at
itamin D deﬁcient levels.
Among the calcium regulating hormones investigated, 25(OH)D
id not change in either the eldecalcitol or alfacalcidol treatment
roups without vitamin D supplementation. Serum 1,25(OH)2D
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ig. 2. Incidence of fractures occurring over 3 years according to serum 25(OH)D at 6 mo
ean  eldecalcitol group and alfacalcidol group, respectively.ed diamonds (), and closed circles (•) represent low tertile (<29.5 ng/mL), middle
t means ± SEM. #, *, and $ p < 0.05 by Student’s t-test compared with pre-treatment
increased by approximately 20% in the alfacalcidol treatment group
but decreased by approximately 50% in the eldecalcitol treatment
group, regardless of the value of 25(OH)D at 6 months. In regard
to the mechanism whereby eldecalcitol reduces serum 1,25(OH)2D
concentration, eldecalcitol is shown to drastically induce CYP24A1
and suppress CYP27B1 in the kidney [4]. In contrast, because alfa-
calcidol itself is converted to calcitriol, the net effect is a slight
increase in serum 1,25(OH)2D concentration. On the other hand, the
effect of eldecalcitol in suppressing intact PTH tends to be slightly
weaker than that of alfacalcidol. Previous basic and clinical stud-
ies have shown that the effect of eldecalcitol in suppressing PTH
is lower than that of calcitriol or alfacalcidol [9,10]. As a result, we
speculate that eldecalcitol decreases serum 1,25(OH)2D concentra-
tion without much changes in serum PTH level.
The present study has limitations. In this study, supplemen-
tation with native vitamin D3 was given if the patient’s serum
25(OH)D was below 20 ng/mL. Therefore, serum 25(OH)D at 6
months was  relatively high. According to the result of a previous
study by eldecalcitol, in which native vitamin D3 supplementation
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as not given, there was no correlation between serum 25(OH)D
oncentration and the increase in lumbar BMD  [11]. However,
ecause there was a large variation in the change in BMD  by
ldecalcitol among subjects with serum 25(OH)D below 20 ng/mL,
rospective studies with and without vitamin D supplementation
re necessary to investigate its inﬂuence on the efﬁcacy of eldecal-
itol.
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